Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hana Yoshida

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Pediatrics: X|June 19, 2023
Conjunctival Pyogenic GranulomaHana Yoshida, Satoko Tominaga, Shinji Makino
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 12, 2024
Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocolHana Yoshida, Satoru Inoda, Hidenori Takahashi, et al.
Scientific Reports|April 20, 2024
One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatmentHironori Takahashi, Satoru Inoda, Hidenori Takahashi, et al.
Ophthalmology and Therapy|August 2, 2023
Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment HistorySatoru Inoda, Hidenori Takahashi, Ryota Takahashi, et al.
Investigative Ophthalmology & Visual Science|January 3, 2024
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With BrolucizumabYuto Hashimoto, Satoru Inoda, Hidenori Takahashi, et al.
Journal of Medical Case Reports|February 28, 2024
Scleritis following intravitreal brolucizumab injection: a case seriesTakuya Takayama, Satoru Inoda, Hidenori Takahashi, et al.
Translational Vision Science & Technology|February 20, 2025
Effect of Combination Use of Aqueous Humor Secretion Inhibitor Eye Drops on Aflibercept Level: A Preliminary AnalysisSatoru Inoda, Hidenori Takahashi, Ryota Takahashi, et al.
International Ophthalmology|August 9, 2025
Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degenerationRyo Terao, Ryo Obata, Atsushi Okubo, et al.
Scientific Reports|December 30, 2025
One year outcomes of intravitreal faricimab for treatment Naïve neovascular AMD and associations with baseline aqueous humor cytokinesSatoru Inoda, Hidenori Takahashi, Yuto Hashimoto, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 29, 2025
Increased aqueous flare after intravitreal brolucizumab injections compared to aflibercept in neovascular age-related macular degenerationYuto Hashimoto, Yusuke Arai, Hidenori Takahashi, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Pediatrics: X|June 19, 2023
Conjunctival Pyogenic GranulomaHana Yoshida, Satoko Tominaga, Shinji Makino
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|July 12, 2024
Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocolHana Yoshida, Satoru Inoda, Hidenori Takahashi, et al.
Scientific Reports|April 20, 2024
One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatmentHironori Takahashi, Satoru Inoda, Hidenori Takahashi, et al.
Ophthalmology and Therapy|August 2, 2023
Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment HistorySatoru Inoda, Hidenori Takahashi, Ryota Takahashi, et al.
Investigative Ophthalmology & Visual Science|January 3, 2024
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With BrolucizumabYuto Hashimoto, Satoru Inoda, Hidenori Takahashi, et al.
Journal of Medical Case Reports|February 28, 2024
Scleritis following intravitreal brolucizumab injection: a case seriesTakuya Takayama, Satoru Inoda, Hidenori Takahashi, et al.
Translational Vision Science & Technology|February 20, 2025
Effect of Combination Use of Aqueous Humor Secretion Inhibitor Eye Drops on Aflibercept Level: A Preliminary AnalysisSatoru Inoda, Hidenori Takahashi, Ryota Takahashi, et al.
International Ophthalmology|August 9, 2025
Aqueous humor cytokine profile in insufficient responder to aflibercept for neovascular age-related macular degenerationRyo Terao, Ryo Obata, Atsushi Okubo, et al.
Scientific Reports|December 30, 2025
One year outcomes of intravitreal faricimab for treatment Naïve neovascular AMD and associations with baseline aqueous humor cytokinesSatoru Inoda, Hidenori Takahashi, Yuto Hashimoto, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|November 29, 2025
Increased aqueous flare after intravitreal brolucizumab injections compared to aflibercept in neovascular age-related macular degenerationYuto Hashimoto, Yusuke Arai, Hidenori Takahashi, et al.
Pageof 2